Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection

Trends in Immunology

Volumn 32, Issue 5, 2011, Pages 219-224

  Alter, Galit ^a   Altfeld, Marcus ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NONHUMAN; REVIEW; VIRUS IMMUNITY;

ADAPTIVE IMMUNITY; CELL COMMUNICATION; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL;

EID: 79955583499     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2011.02.003     Document Type: Review

References (67)

1. Steinbrink K., et al. Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance?. Hum. Immunol. 2009, 70:289-293. 10.1016/j.humimm.2009.02.003.
2. Steinman R.M., Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 2006, 311:17-58.
3. Steinman R.M. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 2007, 37(Suppl 1):S53-S60. 10.1002/eji.200737400.
4. Steinman R.M. Linking innate to adaptive immunity through dendritic cells. Novartis Found. Symp. 2006, 279:101-109. discussion 109-113, 216-109.
5. Walzer T., et al. Natural-killer cells and dendritic cells: " l'union fait la force" Blood 2005, 106:2252-2258. 10.1182/blood-2005-03-1154.
6. Walzer T., et al. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. Expert Opin. Biol. Ther. 2005, 5(Suppl 1):S49-S59. 10.1517/14712598.5.1.S49.
7. Ferlazzo G. Natural killer and dendritic cell liaison: recent insights and open questions. Immunol. Letters 2005, 101:12-17. 10.1016/j.imlet.2005.04.015.
8. Moretta A., et al. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol. 2005, 26:668-675. 10.1016/j.it.2005.09.008.
9. Inaba K., et al. Dendritic cells as antigen presenting cells in vivo. Int. Rev. Immunol. 1990, 6:197-206.
10. Moretta A., et al. What is a natural killer cell?. Nat. Immunol. 2002, 3:6-8.
11. Moretta L., et al. Human NK-cell receptors. Immunol Today 2000, 21:420-422.
12. Lanier L.L. NK cell receptors. Annu. Rev. Immunol. 1998, 16:359-393.
13. Karre K. NK cells, MHC class I molecules and the missing self. Scand. J. Immunol. 2002, 55:221-228.
14. Cooper M.A., et al. The biology of human natural killer-cell subsets. Trends Immunol. 2001, 22:633-640.
15. Fehniger T.A., et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057.
16. Gerosa F., et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J. Immunol. 2005, 174:727-734.
17. Granelli-Piperno A., et al. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:7669-7674. 10.1073/pnas.0402431101.
18. Vitale M., et al. NK-dependent DC maturation is mediated by TNF-α and IFN-γ released upon engagement of the NKp30 triggering receptor. Blood 2005, 106:566-571.
19. Ferlazzo G., et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 2002, 195:343-351.
20. Colonna M., et al. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226. 10.1038/ni1141.
21. Romagnani C., et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur. J. Immunol. 2005, 35:2452-2458. 10.1002/eji.200526069.
22. Jinushi M., et al. Critical role of MHC class I-related chain A and B expression on IFN-(-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection. J. Immunol. 2003, 170:1249-1256.
23. Martin-Fontecha A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-γ for T(H)1 priming. Nat. Immunol. 2004, 5:1260-1265. 10.1038/ni1138.
24. Ferlazzo G., et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16606-16611. 10.1073/pnas.0407522101.
25. Granucci F., et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J. Exp. Med. 2004, 200:287-295. 10.1084/jem.20040370.
26. Koka R., et al. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J. Immunol. 2004, 173:3594-3598.
27. Lucas M., et al. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007, 26:503-517. 10.1016/j.immuni.2007.03.006.
28. Borg C., et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004, 104:3267-3275. 10.1182/blood-2004-01-0380.
29. Hansson M., et al. In vivo function of natural killer cells as regulators of myeloid precursor cells in the spleen. Eur. J. Immunol. 1988, 18:485-488. 10.1002/eji.1830180326.
30. Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin Immunol. 1995, 7:83-88. 10.1006/smim.1995.0012.
31. Pisa P., et al. Activated natural killer cells suppress myelopoiesis in mice with severe combined immunodeficiency. Scand. J. Immunol. 1993, 37:529-532.
32. Della Chiesa M., et al. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. 2003, 33:1657-1666. 10.1002/eji.200323986.
33. Castriconi R., et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4120-4125. 10.1073/pnas.0730640100.
34. Alter G., et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005, 106:3366-3369.
35. Alter G., et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J. Infect. Dis. 2007, 195:1452-1460.
36. Mavilio D., et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2886-2891.
37. Mavilio D., et al. Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J. Exp. Med. 2006, 203:2339-2350.
38. Tasca S., et al. Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. AIDS 2003, 17:2291-2298.
39. Brooks D.G., et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12:1301-1309. 10.1038/nm1492.
40. Brooks D.G., et al. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 2008, 205:533-541. 10.1084/jem.20071948.
41. Fiorentino D.F., et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991, 146:3444-3451.
42. de Waal Malefyt R., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991, 174:915-924.
43. Willems F., et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 1994, 24:1007-1009.
44. Steinbrink K., et al. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 1997, 159:4772-4780.
45. Alter G., et al. IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. J. Clin. Invest. 2010, 120:1905-1913. 10.1172/JCI40913.
46. Scalzo A.A., et al. Genetic mapping of Cmv1 in the region of mouse chromosome 6 encoding the NK gene complex-associated loci Ly49 and musNKR-P1. Genomics 1995, 27:435-441. 10.1006/geno.1995.1074.
47. Webb J.R., et al. Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match. Genes Immun. 2002, 3:250-262. 10.1038/sj.gene.6363876.
48. Dokun A.O., et al. Specific and nonspecific NK cell activation during virus infection. Nat. Immunol. 2001, 2:951-956.
49. Andrews D.M., et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J. Exp. Med. 2010, 207:1333-1343. 10.1084/jem.20091193.
50. Robbins S.H., et al. Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog. 2007, 3:e123. 10.1371/journal.ppat.0030123.
51. Martin M.P., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 2002, 31:429-434.
52. Martin M.P., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 2007, 39:733-740.
53. Alter G., et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:6798-6805. 10.1128/JVI.00256-09.
54. Alter G., et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 2007, 204:3027-3036.
55. Kim S., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
56. Anfossi N., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342. 10.1016/j.immuni.2006.06.013.
57. Brodin P., et al. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 2009, 113:2434-2441. 10.1182/blood-2008-05-156836.
58. Kim S., et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3053-3058.
59. Simon V., et al. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006, 368:489-504. 10.1016/S0140-6736(06)69157-5.
60. Brenchley J.M., Douek D.C. The mucosal barrier and immune activation in HIV pathogenesis. Curr. Opin. HIV AIDS 2008, 3:356-361. 10.1097/COH.0b013e3282f9ae9c.
61. Manaster I., Mandelboim O. The unique properties of human NK cells in the uterine mucosa. Placenta 2008, 29(Suppl A):S60-S66. 10.1016/j.placenta.2007.10.006.
62. Hanna J., Mandelboim O. When killers become helpers. Trends Immunol. 2007, 28:201-206. 10.1016/j.it.2007.03.005.
63. Trundley A., Moffett A. Human uterine leukocytes and pregnancy. Tissue Antigens 2004, 63:1-12.
64. + subset expressing natural killer markers and a singular pattern of adhesion molecules. Scand. J. Immunol. 2000, 52:1-6.
65. + intraepithelial lymphocyte subset in human duodenal biopsies: potential diagnostic value in coeliac disease. Cytometry 1998, 34:95-102. 10.1002/(SICI)1097-0320(19980415)34.
66. Cella M., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
67. Cella M., et al. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1β reveals intrinsic functional plasticity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10961-10966. 10.1073/pnas.1005641107.